课题基金 / 基金详情

Heartland Institute for Clinical and Translational Research

Heartland Institute for Clinical and Translational Research
哈特兰临床与转化研究所
批准号:
8270452
负责人:
Richard J. Barohn
金额:
$319.78万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2016-02-29

项目摘要

项目成果

Richard J. Barohn的其他基金

相关文献

中文摘要
翻译
堪萨斯大学哈特兰临床与转化研究所(University of Kansas Heartland Institute for Clinical and Translational Research,简称CTTR) 2007年成立,以响应国家CTSA倡议。该委员会的愿景是改善 堪萨斯州的健康,通过创建一个新颖的和变革性的转化研究企业, 社区的床边。我们的药物治疗计划的特别优势是一个创业药物和设备 发现和发展计划,以及一个发展良好,高度完成的社区为基础的 研究计划。该研究所的具体目标是:1)创造一个新的学术家园, 临床和翻译研究者的培训计划; 2)提供增强的协调 转化研究基础设施; 3)积极参与社区开发,测试, 通过利用和扩大现有网络传播研究成果,以改善所有人的健康 堪萨斯州人,特别是那些在农村,服务不足和其他目标社区。拟议的基础设施 和教育计划将解决面临的临床和翻译的挑战, 调查人员通过加强和整合现有资源,以更容易获得,开发新的创新 资源,并利用整个大学的研究中心的资源,包括我们的KINBRE 和五个COBRE赠款~和我们的COBTR网络机构。为了实现我们的目标,我们 在规划、发展、 并建立了一个反恐怖组织。该项目将提供新的基础设施、培训和教育 支持研究者临床和转化研究的计划,将实验室发现首先 人类试验(Tl研究),并将研究转移到传播和实施研究 将研究成果转化为实践(T2研究)。在机构和社区的大力支持下,我们 已经取得了巨大的进步。来自CTSA计划的资金将允许大学 堪萨斯州有机会充分发挥其潜力,不仅为我们的地区,而且还有助于 国家CTSA联盟。
英文摘要
The University of Kansas Heartland Institute for Clinical and Translational Research (HICTR) was established in 2007 in response to the national CTSA initiative. The vision of the HICTR is to improve the health of Kansans by creating a novel and transformative translational research enterprise from bench to bedside to community. Particular strengths of our HICTR program are an entrepreneurial drug and device discovery and development program and a well-developed and highly accomplished community-based research program. The specific aims of the HICTR are to: 1) create a new academic home with innovative training programs for clinical and translational Investigators; 2) provide an enhanced coordinated translational research infrastructure; and 3) actively engage the community in developing, testing, and disseminating research, by capitalizing on and expanding existing networks, to improve the health of all Kansans¿especially those in rural, underserved and other target communities. The proposed infrastructure and educational programs of the HICTR will address the challenges facing clinical and translational investigators by enhancing and integrating existing resources for easier access, developing new innovative resources, and capitalizing on resources residing in research centers across the university¿including our KINBRE and five COBRE grants~and our HICTR network institutions. In support of our aims, we have marshaled an impressive array of institutional, corporate, and community resources in planning, developing, and establishing the HICTR. The HICTR will provide new infrastructure and training and educational programs to support investigators' clinical and translational research¿taking laboratory discoveries to first trials in humans (Tl research) and moving research through to studies on dissemination and implementation of research findings to practice (T2 research). With extraordinary institutional and community support, we already have made tremendous progress. Funding from the CTSA program will allow the University of Kansas' HICTR the opportunity to fully realize its potential not only for our region, but also to contribute to the national CTSA Consortium.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Frontiers: University of Kansas Clinical and Translational Science Institute
Frontiers: University of Kansas Clinical and Translational Science Institute
Models of Neuromuscular Disease Across the Lifespan
A Phase II Trial of Rituximab In Myasthenia Gravis
  • 批准号:
    8644497
  • 项目类别:
  • 资助金额:
    $130.54万
  • 财政年份:
    2013
  • 负责人:
    Richard J. Barohn
  • 依托单位: